Awardee OrganizationWEILL MEDICAL COLL OF CORNELL UNIV
Description
Abstract Text
Overall, Abstract
Despite the availability of therapy, Mycobacterium tuberculosis (Mtb) is the major infectious killer of adults.
Finding more effective therapeutic strategies will require a better understanding of the fundamental biology of
bacterial growth, metabolism and interaction with the host. This program proposes to understand key pathways
in Mtb biology using advanced genetic and biochemical methods, with a particular focus on complex
pathways important in adaptation to disease-relevant stressors. “Pathways” is defined broadly, including
biochemical, structural and genetic interactions. In many cases, traditional genetic approaches to discover and
understand these pathways are limited, but many of the most critical aspects of Mtb biology are mediated by
such complex genetic mechanisms. This program will leverage new methodology and resources that the
collaborators have developed in the last few years, to discover the constituents of key pathways, attribute
functions to new pathways, and understand the mechanisms which underlie the ability of bacteria to survive and
grow under a variety of conditions, focusing on those encountered during infection. They will also take advantage
of the close collaborations among the investigators who have worked well together for several years. The work
will be organized into four projects and four cores, but considerable crossover is expected, which will enrich each
component.
Project 1. Metabolic adaptations required for growth and virulence of Mtb at acidic pH.
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
Project 3. Defining the RNA processing and degradation pathways of Mtb.
Project 4. Defining cell division pathways in Mtb.
Core A. Metabolomics and lipidomics.
Core B. Biochemistry and enzymology.
Core C. Bioinformatics and data sharing.
Core D. Administration.
All of this work will be facilitated by a highly collaborative group of investigators, almost all of whom have worked
together for many years on a large variety of projects. Both project and core investigators will serve as full-
fledged intellectual contributors, enabling the team to bring a variety of approaches and thinking to bear on
complex biological systems.
Public Health Relevance Statement
Project Narrative
Tuberculosis is a major global health burden, killing more than 1.5 million people every year, despite the
availability of therapy. Finding more effective therapeutic strategies could transform the epidemic, but that will
require a better understanding of the fundamental biology of bacterial growth, metabolism and interaction with
the host of the causative agent – Mycobacterium tuberculosis (Mtb). This proposal aims to make advances
toward this goal, utilizing innovative techniques to understand therapeutically relevant pathways in Mtb.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
060217502
UEI
YNT8TCJH8FQ8
Project Start Date
12-June-2020
Project End Date
31-May-2025
Budget Start Date
01-June-2021
Budget End Date
31-May-2022
Project Funding Information for 2021
Total Funding
$2,492,917
Direct Costs
$2,118,454
Indirect Costs
$374,463
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$2,492,917
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI143575-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI143575-02
Patents
No Patents information available for 5P01AI143575-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI143575-02
Clinical Studies
No Clinical Studies information available for 5P01AI143575-02
News and More
Related News Releases
No news release information available for 5P01AI143575-02
History
No Historical information available for 5P01AI143575-02
Similar Projects
No Similar Projects information available for 5P01AI143575-02